Monoclonal antibody therapy for central nervous system lymphomas: an emerging treatment paradigm.
The management of CNS lymphomas is poised for another revolution due to the emergence of therapeutic monoclonal antibodies. As the technology for generating monoclonal antibodies matures and obstacles are solved, therapeutic monoclonal antibodies will play an increasing role in the management of cancer. This article will review the biology of CNS lymphomas, monoclonal antibody technology, limitation of existing chemotherapies and the application of therapeutic monoclonal antibodies for the treatment of CNS lymphomas.